Approved for use through 10/31/2002. OMB 0851-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Passwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a wait CMB portion number.

Substitute for form 1449A/PTO Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of

2

(use as many sheets as necessary)

1

Sheet

Examiner

Application Number	10/551,998	
Filing Date	October 5, 2006	_
First Named Invento	Kai SCHIEMANN, et al.	_
Group Art Unit	1626	_
Examiner Name	CHU, Yong Liang	
Attorney Docket Nu	nber MERCK-3073	

U.S. PATENT DOCUMENTS							
Cite No.1	U.S. Patent Doo	cument Kind Gode ² (<i>if known</i>)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
	Cite No. ³		U.S. Patent Document Kind Code ²	U.S. Patent Document Kind Code ² Name of Patentee or Applicant			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No 1	Office ^a	Foreign Patent Docum Number ⁴	Kind Coda ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Data of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁰
/Y.C./	B1	wo	01/29008		ARENA PHARMACEUTICALS INC.	04-26-2001		
/Y.C./	B2	wo	96/33175	Α	SEARLE & CO	10-24-1996		
**	B3	-DE-	21-41-125	А	BYK-GULDEN LOMBERG GMBH	02-24-1072		
/Y.C./	B4	wo	03/099793	Α	TAKEDA LTD	12-04-2003		
/Y.C./	B5	WO	2004/024705	Α	TAKEDA LTD.	03-25-2004		
/Y.C./	B6	wo	2004/037248	Α	CAREX SA	05-06-2004		
**	B7	DE	2201689	Α	Merck Patent GmbH	07-19-1973		*****
	B8	DE	2258033	Α	Merck-Patent-EmbH	05-99-1974		
**	B9	DE	2906252	A	Merck Ratent GmbH	08-28-1980		

Signature	/Yong Chu/	Considered	07/30/2008		
EXAMINER: Initi	al if reference considered, whether or not citation is in	conformance with MPEP	609. Draw line through	citation if not in conformance	

Date

Burden Nor Statement. This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form standed be sent to the Chief Information Office, U.S. Pationt and Trademark. Office. Washington, D.C. 2023. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner of Patents, P.O. 80x 1450. Alexandria, V.A.2231-4.50x.

and not considered. Include copy of this form with next communication to applicant.

¹ Urisive crision designation number. ² See attached Kinds of U.S., Palent Documents. ² Enter Office that issued the document, by the two-letter code WPO Standard Shy. ¹ For Japanese patent documents, the indication of the year of the ringin of the Emperor naval processe line serior imprise of the patent document. ² Kind of document by the appropriate symbols as indicated on the document under WPO Standard Sh. 16 if possible. ³ Applicant is to place a chacker mark here et English in squages Corresponding family members.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Palent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Learnery for the conference of conference and the conference of the conference

		Under the Paperwo	rk Redu	ction Act of 1995, no persons	are required to respond to a collection of	information unless it contains a valid OMB control number
	Substitute t	or form 1449A/PTC)			Complete if Known
	INFO	ORA TION	DIO	01.001105	Application Number	10/551,998
				CLOSURE	Filing Date	October 5, 2006
	STAT	EMENTB	YA	PPLICANT	First Named Inventor	Kai SCHIEMANN, et al.
					Group Art Unit	1626
	(use as many she	ets as	necessary)	Examiner Name	CHU, Yong Liang
$\overline{}$	Sheet	2	of	2	Attorney Docket Number	MERCK-3073

Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т
/Y.C.	C1	TAKEHITO OCHI ET AL.: "FR43166 ATTENUATES SPINAL PAIN TRANSMISSION THROUGH ACTIVATION OF THE SEROTONIG SYSTEM" EUROPEAN JOURNAL OF PHARMACOLOGY, Bd. 452, 2002, Pages 319-324, XP002284173, The Enlire Document.	
/Y.C	/ C2	YOSHIKO SUZUKI ET AL: "IN VITRO AND IN VIVO PHARMACOLOGICAL PROFILE OF 4-(4-FLUOROPHEN)L-1-(2-5-(4-FLUOROPHEN)L-1-H-PYRAZOL-4-YLIETHYL) PIFERIDINE (IRAD161)* LIFE SCIENCES, Bd. 71, 2002, pages 2603-2615, XP02228474, The Entire Document.	
/Y.C./	СЗ	KATRITZKY ET AL: "1,3-DIPOLAR CYCLOADDITIONS OF ELECTRON-RICH BENZOTRIAZOL-1- YLPROPENES" J. HETEROCYCLIC CHEM., Bd. 33, 1996, Pages 1637-1646, XP002284475, Figure 26, Pages 1640.	
/Y.C./	C4	PEREZ ET AL: "AN EASY METHOD FOR THE N-ALKYLATION OF AMIDES, CARBAMATES, UREAS AND AZOLES" HETEROCYCLES, Bd. 60, Nr. 1, 25 November 2002, Pages 167-175, XP002284476, Figures 10,11 and 12, Pages 168 and 173.	
/Y.C./	C5	O'BRIAN ET AL: "SOME REACTIONS OF 3-HYDROXY-1-PHENYLPYRAZOLE" J. ORG. CHEM., Bd.31, 1966, Pages 1538-1542, XP002284477, The Entire Document.	
/Y.C./	C6	DATABASE CHEMABS 'ONLINEI CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1966. GRANDBERG, IJ. ET AL: "PYRAZOLES, XII. HYDROXYAND CHLOROMENTHYLATION OF 1- SUBSTITUTED PYRAZOLES 'YENO2294480, FOUND IN STN, DATABASE ACCESSION NO. 1981;99421, SUMMARY & ZHURNAL OBSHCHEI KHIMII, 30, 3324-8; CODEN: ZOKHA4; ISSN: 0044 400X, 1680.	
/Y.C.	C7	DATABASE BEILSTEIN; BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; 29 NOVEMBER 1988, XPO02254481, DATABASE ACCESSION NO. BRN 1127514 CAS-RN, 35000-58-9 SUMMARY & OON ET ALL; J. PRAKT. CHEM, Bd. 313, 1971, Pages 236-246.	
/Y.C.	C8	BEBERNITZ ET AL.: "THE EFFECT OF 1,3-DIARYL-'1HI-PYRAZOL-4-ACETAMIDES ON GLUCOSE UTILIZATION IN OBJOB MICE' J. MED. CHEM, Bd. 44, Nr. 16, 2001, PAGES 2801-2811, PKP002284478; SCHEMA 1, METHODE A, STRUKTUREN 2-5, REAKTIONEN A AND B.	
/Y.C./	C9	ECHEVARRIA ET AL: RESEARCH IN THE AZOLE SERIES. 102 '11. SYNTHESIS AND 13C NMR STUDY OF PYRAZOLE-4-CARBOXALDEHYDES: J. HETEROCYCLIC CHEM., Bd. 30, 1993, PAGES 957-980, XPO2284479, FORMULA 19, PAGE 957.	
/Y.C	C10	DATABASE BEILSTEIN, BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; 24 JANUARY 2002, XP002284482, DATABASE ACCESSION NO. BRN 8913586 & BRATENKO ET AL: RUSS. J. ORG. CHEM. EN, Bd. 37, Nr. 4, 2001, PAGES 502-555.	
/Y.C	C11	Abstract of Bratenko Et Al; XP002284482.	

Examiner Signature	/Yong Chu/	Date Considered	07/30/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number: ² Applicant is to place a check mark here if English language Translation is attached

Burden Hore Statement: This form is estimated to take 2.0 hours to complete. Then will very depending upon the nexts of the production comments on the amount of time by us on required to complete this form standal be sent to like Child Industrial, 10.5 had not Tackensative. Office, Weshington, CC 2023: DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO Commissionment of Plantins, P.D. 2023 1450, Meanning, V. 22233-1450.